glp 1 based therapy for diabetes UC Davis Health examines systemic impact of GLP-1–based therapies GLP-1 Type 1 Adjunct Therapy:

Theyre indicated for people who have a BMI of 30 or more, who are considered to have obesity, or who have a BMI of 27 considered overweight or higher and at least one weight-related health condition, like high blood pressure or cholesterol

It is about: who challenges what in paragraph IV or biosimilar-related challenges, where the dispute is litigated (US District Courts for ANDA/biosimilar actions), whether a settlement triggers a launch date (carve-outs can delay or narrow market entry), and how courts interpret claim scope for composition vs method claims

Timing around supplements and other medications Injectable GLP-1 agonists do not have significant drug interactions related to timing because they bypass the gastrointestinal tract

10.1016/j.lfs.2021.119523 91 ShangJ.LiuF.ZhangB.DongK.LuM.JiangR.et al (2021)